{"transactions":[{"id":683653,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22278,"kind":"person","name":"Rolke James","position":1,"cik":"0001693858","reported_name":"Rolke James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-08-18T21:00:12.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":208076,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones."}],"balance_after":422814,"source":{"system":"sec-edgar","filing":"0001193125-26-355663","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526355663/ownership.xml","form_type":"4"}},{"id":683652,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22277,"kind":"person","name":"Chawla Lakhmir S","position":1,"cik":"0001646626","reported_name":"Chawla Lakhmir S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-18T21:00:11.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":32011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones."}],"balance_after":44169,"source":{"system":"sec-edgar","filing":"0001193125-26-355662","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526355662/ownership.xml","form_type":"4"}},{"id":683651,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22276,"kind":"person","name":"Zygmont Chester Stanley III","position":1,"cik":"0001900657","reported_name":"Zygmont Chester Stanley III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-18T21:00:09.000Z","date":"2026-08-17","kind":"gift","planned":false,"acquired":true,"shares":208073,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"by Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee."}],"balance_after":300136,"source":{"system":"sec-edgar","filing":"0001193125-26-355661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526355661/ownership.xml","form_type":"4"}},{"id":683650,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22276,"kind":"person","name":"Zygmont Chester Stanley III","position":1,"cik":"0001900657","reported_name":"Zygmont Chester Stanley III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-18T21:00:09.000Z","date":"2026-08-17","kind":"gift","planned":false,"acquired":false,"shares":208073,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-355661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526355661/ownership.xml","form_type":"4"}},{"id":683649,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22276,"kind":"person","name":"Zygmont Chester Stanley III","position":1,"cik":"0001900657","reported_name":"Zygmont Chester Stanley III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-18T21:00:09.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":208073,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones."}],"balance_after":208073,"source":{"system":"sec-edgar","filing":"0001193125-26-355661","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526355661/ownership.xml","form_type":"4"}},{"id":683648,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22275,"kind":"person","name":"ROPER JESS","position":1,"cik":"0001408993","reported_name":"ROPER JESS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-18T21:00:06.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":32011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones."}],"balance_after":44839,"source":{"system":"sec-edgar","filing":"0001193125-26-355659","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526355659/ownership.xml","form_type":"4"}},{"id":683647,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22274,"kind":"person","name":"CARVER JENNIFER","position":1,"cik":"0001663163","reported_name":"CARVER JENNIFER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-08-18T21:00:04.000Z","date":"2026-08-17","kind":"grant","planned":false,"acquired":true,"shares":32011,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones."}],"balance_after":44769,"source":{"system":"sec-edgar","filing":"0001193125-26-355658","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526355658/ownership.xml","form_type":"4"}},{"id":795786,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22278,"kind":"person","name":"Rolke James","position":1,"cik":"0001693858","reported_name":"Rolke James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-01T21:32:55.000Z","date":"2026-04-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":10115,"price":1.13,"value":11429.95,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.14, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":214738,"source":{"system":"sec-edgar","filing":"0001193125-26-201769","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526201769/ownership.xml","form_type":"4"}},{"id":795785,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22276,"kind":"person","name":"Zygmont Chester Stanley III","position":1,"cik":"0001900657","reported_name":"Zygmont Chester Stanley III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-05-01T21:31:42.000Z","date":"2026-04-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":13285,"price":1.1,"value":14613.5,"ownership":{"direct":false,"nature":"by Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.09 to $1.13, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee."}],"balance_after":92063,"source":{"system":"sec-edgar","filing":"0001193125-26-201764","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526201764/ownership.xml","form_type":"4"}},{"id":917818,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22275,"kind":"person","name":"ROPER JESS","position":1,"cik":"0001408993","reported_name":"ROPER JESS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-05T22:31:20.000Z","date":"2026-02-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":1591,"price":1.85,"value":2943.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026."}],"balance_after":12828,"source":{"system":"sec-edgar","filing":"0001193125-26-039700","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526039700/ownership.xml","form_type":"4"}},{"id":917819,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22277,"kind":"person","name":"Chawla Lakhmir S","position":1,"cik":"0001646626","reported_name":"Chawla Lakhmir S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-05T22:30:45.000Z","date":"2026-02-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":2261,"price":1.85,"value":4182.85,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026."}],"balance_after":12158,"source":{"system":"sec-edgar","filing":"0001193125-26-039695","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526039695/ownership.xml","form_type":"4"}},{"id":917817,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22274,"kind":"person","name":"CARVER JENNIFER","position":1,"cik":"0001663163","reported_name":"CARVER JENNIFER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-02-05T22:30:12.000Z","date":"2026-02-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":1661,"price":1.87,"value":3106.07,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026."}],"balance_after":12758,"source":{"system":"sec-edgar","filing":"0001193125-26-039693","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526039693/ownership.xml","form_type":"4"}},{"id":917815,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22278,"kind":"person","name":"Rolke James","position":1,"cik":"0001693858","reported_name":"Rolke James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-02-05T22:29:45.000Z","date":"2026-02-03","kind":"tax_withholding","planned":false,"acquired":false,"shares":8521,"price":1.86,"value":15849.06,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026."}],"balance_after":224853,"source":{"system":"sec-edgar","filing":"0001193125-26-039690","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526039690/ownership.xml","form_type":"4"}},{"id":917816,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22276,"kind":"person","name":"Zygmont Chester Stanley III","position":1,"cik":"0001900657","reported_name":"Zygmont Chester Stanley III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-05T22:29:23.000Z","date":"2026-02-04","kind":"tax_withholding","planned":false,"acquired":false,"shares":13100,"price":1.65,"value":21615.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.63 to $1.66, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee."}],"balance_after":105348,"source":{"system":"sec-edgar","filing":"0001193125-26-039686","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526039686/ownership.xml","form_type":"4"}},{"id":941097,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22278,"kind":"person","name":"Rolke James","position":1,"cik":"0001693858","reported_name":"Rolke James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-01-12T22:21:07.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":532829,"price":0.9,"value":479546.1,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant."}],"balance_after":933489,"source":{"system":"sec-edgar","filing":"0001193125-26-010648","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526010648/ownership.xml","form_type":"4"}},{"id":941096,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22276,"kind":"person","name":"Zygmont Chester Stanley III","position":1,"cik":"0001900657","reported_name":"Zygmont Chester Stanley III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-12T22:17:29.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":78145,"price":0.9,"value":70330.5,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee."}],"balance_after":473790,"source":{"system":"sec-edgar","filing":"0001193125-26-010642","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526010642/ownership.xml","form_type":"4"}},{"id":941095,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22274,"kind":"person","name":"CARVER JENNIFER","position":1,"cik":"0001663163","reported_name":"CARVER JENNIFER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:12:11.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":41981,"price":0.9,"value":37782.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant."}],"balance_after":57669,"source":{"system":"sec-edgar","filing":"0001193125-26-010625","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526010625/ownership.xml","form_type":"4"}},{"id":941094,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22275,"kind":"person","name":"ROPER JESS","position":1,"cik":"0001408993","reported_name":"ROPER JESS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:08:58.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":41981,"price":0.9,"value":37782.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant."}],"balance_after":57667,"source":{"system":"sec-edgar","filing":"0001193125-26-010613","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526010613/ownership.xml","form_type":"4"}},{"id":941093,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22277,"kind":"person","name":"Chawla Lakhmir S","position":1,"cik":"0001646626","reported_name":"Chawla Lakhmir S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-01-12T22:01:36.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":41981,"price":0.9,"value":37782.9,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant."}],"balance_after":57667,"source":{"system":"sec-edgar","filing":"0001193125-26-010586","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526010586/ownership.xml","form_type":"4"}},{"id":1010693,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22277,"kind":"person","name":"Chawla Lakhmir S","position":1,"cik":"0001646626","reported_name":"Chawla Lakhmir S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-31T17:01:10.000Z","date":"2025-10-29","kind":"grant","planned":false,"acquired":true,"shares":15625,"price":1.28,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026."}],"balance_after":15686,"source":{"system":"sec-edgar","filing":"0001193125-25-260426","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312525260426/ownership.xml","form_type":"4"}},{"id":1010692,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22278,"kind":"person","name":"Rolke James","position":1,"cik":"0001693858","reported_name":"Rolke James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-10-31T16:58:15.000Z","date":"2025-10-29","kind":"grant","planned":false,"acquired":true,"shares":390614,"price":1.28,"value":499985.92,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests quarterly over one year from the grant date."}],"balance_after":400660,"source":{"system":"sec-edgar","filing":"0001193125-25-260423","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312525260423/ownership.xml","form_type":"4"}},{"id":1010691,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22274,"kind":"person","name":"CARVER JENNIFER","position":1,"cik":"0001663163","reported_name":"CARVER JENNIFER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-31T16:56:12.000Z","date":"2025-10-29","kind":"grant","planned":false,"acquired":true,"shares":15625,"price":1.28,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026."}],"balance_after":15688,"source":{"system":"sec-edgar","filing":"0001193125-25-260419","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312525260419/ownership.xml","form_type":"4"}},{"id":1010690,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22276,"kind":"person","name":"Zygmont Chester Stanley III","position":1,"cik":"0001900657","reported_name":"Zygmont Chester Stanley III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-31T16:55:28.000Z","date":"2025-10-29","kind":"grant","planned":false,"acquired":true,"shares":390614,"price":1.28,"value":499985.92,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee."}],"balance_after":395645,"source":{"system":"sec-edgar","filing":"0001193125-25-260417","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312525260417/ownership.xml","form_type":"4"}},{"id":1010689,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22275,"kind":"person","name":"ROPER JESS","position":1,"cik":"0001408993","reported_name":"ROPER JESS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-31T16:54:38.000Z","date":"2025-10-29","kind":"grant","planned":false,"acquired":true,"shares":15625,"price":1.28,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026"}],"balance_after":15686,"source":{"system":"sec-edgar","filing":"0001193125-25-260415","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000119312525260415/ownership.xml","form_type":"4"}},{"id":1269730,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22277,"kind":"person","name":"Chawla Lakhmir S","position":1,"cik":"0001646626","reported_name":"Chawla Lakhmir S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-13T23:14:40.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":181,"price":3.87,"value":700.47,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant."}],"balance_after":181,"source":{"system":"sec-edgar","filing":"0000950170-25-020126","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025020126/ownership.xml","form_type":"4"}},{"id":1269729,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22274,"kind":"person","name":"CARVER JENNIFER","position":1,"cik":"0001663163","reported_name":"CARVER JENNIFER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-13T23:12:17.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":181,"price":3.87,"value":700.47,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant."}],"balance_after":187,"source":{"system":"sec-edgar","filing":"0000950170-25-020120","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025020120/ownership.xml","form_type":"4"}},{"id":1269728,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22275,"kind":"person","name":"ROPER JESS","position":1,"cik":"0001408993","reported_name":"ROPER JESS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-13T23:09:20.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":181,"price":3.87,"value":700.47,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant."}],"balance_after":183,"source":{"system":"sec-edgar","filing":"0000950170-25-020113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025020113/ownership.xml","form_type":"4"}},{"id":1269727,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22278,"kind":"person","name":"Rolke James","position":1,"cik":"0001693858","reported_name":"Rolke James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2025-02-13T23:07:18.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":30095,"price":3.87,"value":116467.65,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant."}],"balance_after":30137,"source":{"system":"sec-edgar","filing":"0000950170-25-020109","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025020109/ownership.xml","form_type":"4"}},{"id":1269726,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22276,"kind":"person","name":"Zygmont Chester Stanley III","position":1,"cik":"0001900657","reported_name":"Zygmont Chester Stanley III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-02-13T23:05:34.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":15048,"price":3.87,"value":58235.76,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee."}],"balance_after":15076,"source":{"system":"sec-edgar","filing":"0000950170-25-020104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025020104/ownership.xml","form_type":"4"}},{"id":1269725,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-13T23:03:01.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":181,"price":3.87,"value":700.47,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust"}],"balance_after":268,"source":{"system":"sec-edgar","filing":"0000950170-25-020097","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017025020097/ownership.xml","form_type":"4"}},{"id":1714419,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-12-12T21:48:50.000Z","date":"2023-12-08","kind":"sale","planned":false,"acquired":false,"shares":27771,"price":0.5199,"value":14438.1429,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-058296","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123058296/doc4.xml","form_type":"4"}},{"id":1758189,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-18T21:15:45.000Z","date":"2023-10-16","kind":"sale","planned":false,"acquired":false,"shares":1845,"price":0.6501,"value":1199.4345,"ownership":{"direct":true},"balance_after":27771,"source":{"system":"sec-edgar","filing":"0001209191-23-053102","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123053102/doc4.xml","form_type":"4"}},{"id":1759064,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-17T20:12:08.000Z","date":"2023-10-16","kind":"sale","planned":false,"acquired":false,"shares":10957,"price":0.661,"value":7242.577,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee."}],"balance_after":42096,"source":{"system":"sec-edgar","filing":"0001209191-23-052953","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123052953/doc4.xml","form_type":"4"}},{"id":1770552,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-10-02T20:09:31.000Z","date":"2023-09-28","kind":"sale","planned":false,"acquired":false,"shares":1429,"price":0.69,"value":986.01,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee."}],"balance_after":42096,"source":{"system":"sec-edgar","filing":"0001209191-23-051037","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123051037/doc4.xml","form_type":"4"}},{"id":1779000,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-18T21:18:36.000Z","date":"2023-09-18","kind":"sale","planned":false,"acquired":false,"shares":4000,"price":0.74,"value":2960.0,"ownership":{"direct":true},"balance_after":39348,"source":{"system":"sec-edgar","filing":"0001209191-23-049786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123049786/doc4.xml","form_type":"4"}},{"id":1778999,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-18T21:18:36.000Z","date":"2023-09-15","kind":"sale","planned":false,"acquired":false,"shares":9500,"price":0.73,"value":6935.0,"ownership":{"direct":true},"balance_after":43348,"source":{"system":"sec-edgar","filing":"0001209191-23-049786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123049786/doc4.xml","form_type":"4"}},{"id":1778998,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-18T21:18:36.000Z","date":"2023-09-14","kind":"sale","planned":false,"acquired":false,"shares":12000,"price":0.75,"value":9000.0,"ownership":{"direct":true},"balance_after":52848,"source":{"system":"sec-edgar","filing":"0001209191-23-049786","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123049786/doc4.xml","form_type":"4"}},{"id":1917293,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-19T22:00:11.000Z","date":"2023-04-18","kind":"purchase","planned":false,"acquired":true,"shares":25000,"price":1.16,"value":29000.0,"ownership":{"direct":true},"balance_after":64848,"source":{"system":"sec-edgar","filing":"0001209191-23-024898","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123024898/doc4.xml","form_type":"4"}},{"id":1917292,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-04-19T22:00:11.000Z","date":"2023-04-17","kind":"purchase","planned":false,"acquired":true,"shares":26500,"price":1.16,"value":30740.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted-average price at which shares were purchased within a range between $1.14 and $1.17. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":39848,"source":{"system":"sec-edgar","filing":"0001209191-23-024898","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123024898/doc4.xml","form_type":"4"}},{"id":1918208,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-18T20:08:29.000Z","date":"2023-04-14","kind":"grant","planned":false,"acquired":true,"shares":6356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable on the grant date."}],"balance_after":6356,"derivative":{"exercise_price":1.19,"expiration_date":"2033-04-14","underlying":"Common Stock","underlying_shares":6356},"source":{"system":"sec-edgar","filing":"0001209191-23-024646","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123024646/doc4.xml","form_type":"4"}},{"id":1918207,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22275,"kind":"person","name":"ROPER JESS","position":1,"cik":"0001408993","reported_name":"ROPER JESS","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-18T20:07:21.000Z","date":"2023-04-14","kind":"grant","planned":false,"acquired":true,"shares":6356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable on the grant date."}],"balance_after":6356,"derivative":{"exercise_price":1.19,"expiration_date":"2033-04-14","underlying":"Common Stock","underlying_shares":6356},"source":{"system":"sec-edgar","filing":"0001209191-23-024643","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123024643/doc4.xml","form_type":"4"}},{"id":1918206,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":114387,"kind":"person","name":"LaBelle Curt H","position":1,"cik":"0001396235","reported_name":"LaBelle Curt H","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-18T20:04:47.000Z","date":"2023-04-14","kind":"grant","planned":false,"acquired":true,"shares":6356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable on the grant date."}],"balance_after":6356,"derivative":{"exercise_price":1.19,"expiration_date":"2033-04-14","underlying":"Common Stock","underlying_shares":6356},"source":{"system":"sec-edgar","filing":"0001209191-23-024638","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123024638/doc4.xml","form_type":"4"}},{"id":1918205,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22274,"kind":"person","name":"CARVER JENNIFER","position":1,"cik":"0001663163","reported_name":"CARVER JENNIFER","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-04-18T20:03:02.000Z","date":"2023-04-14","kind":"grant","planned":false,"acquired":true,"shares":6356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options vest and become exercisable on the grant date."}],"balance_after":6356,"derivative":{"exercise_price":1.19,"expiration_date":"2033-04-14","underlying":"Common Stock","underlying_shares":6356},"source":{"system":"sec-edgar","filing":"0001209191-23-024634","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123024634/doc4.xml","form_type":"4"}},{"id":1987360,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22276,"kind":"person","name":"Zygmont Chester Stanley III","position":1,"cik":"0001900657","reported_name":"Zygmont Chester Stanley III","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-28T21:09:40.000Z","date":"2023-02-25","kind":"grant","acquired":true,"shares":611,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were granted on 2/25/2022 and  vest 25% on the one-year anniversary of the grant date, and thereafter quarterly over a three-year period, subject to continued service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":49,"expiration_date":"2032-02-25","underlying":"Common Stock","underlying_shares":611},"source":{"system":"sec-edgar","filing":"0001209191-23-013633","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123013633/doc4.xml","form_type":"4"}},{"id":1987359,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":22278,"kind":"person","name":"Rolke James","position":1,"cik":"0001693858","reported_name":"Rolke James","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-28T21:08:00.000Z","date":"2023-02-25","kind":"grant","acquired":true,"shares":2542,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock options were granted on 2/25/2022 and  vest 25% on the one-year anniversary of the grant date, and thereafter quarterly over a three-year period, subject to continued service through each such vesting date."}],"balance_after":0,"derivative":{"exercise_price":49,"expiration_date":"2032-02-25","underlying":"Common Stock","underlying_shares":2542},"source":{"system":"sec-edgar","filing":"0001209191-23-013629","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919123013629/doc4.xml","form_type":"4"}},{"id":2017775,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":116949,"kind":"organization","name":"AXA IM Prime Impact Master Fund I SCA SICAV-RAIF","position":1,"cik":"0001884552","reported_name":"AXA IM Prime Impact Master Fund I SCA SICAV-RAIF","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% Owner"}},{"id":116950,"kind":"organization","name":"AXA IM Prime Impact GP S.a.r.l","position":2,"cik":"0001965500","reported_name":"AXA IM Prime Impact GP S.a.r.l","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":103806,"kind":"organization","name":"AXA Investment Managers Paris","position":3,"cik":"0001577619","reported_name":"AXA Investment Managers Paris","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":98551,"kind":"organization","name":"AXA INVESTMENT MANAGERS UK Ltd","position":4,"cik":"0001536140","reported_name":"AXA INVESTMENT MANAGERS UK Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":103824,"kind":"organization","name":"AXA Investment Managers S.A.","position":5,"cik":"0001826635","reported_name":"AXA Investment Managers S.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}},{"id":97691,"kind":"organization","name":"AXA S.A.","position":6,"cik":"0000898427","reported_name":"AXA S.A.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Former 10% owner"}}],"security":"Common stock","published_at":"2023-02-14T17:28:32.000Z","date":"2022-01-10","kind":"other","acquired":true,"shares":1958984,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of\npublicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement"},{"field":"kind","element":"transactionCoding","label":"F1","text":"On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of\npublicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement"},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of\npublicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement"},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of\npublicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 10, 2022, Petra Acquisition, Inc. consummated a business combination with the old Revelation Biosciences, Inc., and the reporting persons became the holders of\npublicly traded shares of the Common Stock of the new Revelation Biosciences, Inc., pursuant to a registration statement"},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The following parties may be deemed to have the power to vote and direct the disposition of the shares of Common Stock owned by AXA IM Prime Impact Master Fund ISCA\nSICAV-RAIF (the \"Fund\"):(a) the Fund owns the shares of Common Stock reported herein, (b) the general partner of the Fund, AXA IM Prime Impact GP S.a.r.l, has appointed\nAXA Investment Managers Paris S.A. (\"AIFM\") as the alternative investment fund manager of the Fund to undertake all functions required of an external alternative investment\nfund manager, (c) the Fund with the consent of AIFM and duly represented by its general partner, AXA IM Prime Impact GP S.a.r.l, has also entered into a delegated portfolio\nmanagement agreement with AIFM and AXA Investment Managers UK Ltd. (\"AXA IM UK\") in order to appoint AXA IM UK to act as the portfolio manager of the Fund, (d) AXA\nInvestment Managers S.A. is the sole shareholder of AIFM and AXA IM UK, and (e) AXA S.A. is the controlling shareholder of AXA IM SA."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The reporting persons do not believe that they constitute a \"group\" within the meaning of Rule 13d-5 under the Securities Exchange Act of 1934, as amended, and they do not\nbelieve that they are otherwise required to attribute to each other the beneficial ownership of the securities reported herein held by them or by any persons or entities for whom\nor for which AIFM or AXA IM UK provides investment management services. Each of the reporting persons also disclaims beneficial ownership of these securities except to the\nextent of that person's pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"On July 28, 2022, the issuer closed a public offering, and, as a result of the dilutive effect of the public offering, the reporting persons ceased to beneficially own more than\n10% of the issuer's Common Stock outstanding as of the close of business on July 28, 2022."}],"balance_after":1958984,"source":{"system":"sec-edgar","filing":"0001884552-23-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/898427/000188455223000001/primary_doc.xml","form_type":"5"}},{"id":2369203,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-28T23:29:04.000Z","date":"2022-02-25","kind":"purchase","acquired":true,"shares":20000,"price":1.6,"value":32000.0,"ownership":{"direct":true},"balance_after":467156,"source":{"system":"sec-edgar","filing":"0001209191-22-013741","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919122013741/doc4.xml","form_type":"4"}},{"id":2404480,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-10T23:22:45.000Z","date":"2022-02-09","kind":"purchase","acquired":true,"shares":30000,"price":2.5533,"value":76599.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted-average price at which shares were purchased within a range between $2.53 and $2.57. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":447156,"source":{"system":"sec-edgar","filing":"0001209191-22-008580","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919122008580/doc4.xml","form_type":"4"}},{"id":2404479,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-10T23:22:45.000Z","date":"2022-02-08","kind":"purchase","acquired":true,"shares":1000,"price":2.54,"value":2540.0,"ownership":{"direct":true},"balance_after":417156,"source":{"system":"sec-edgar","filing":"0001209191-22-008580","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919122008580/doc4.xml","form_type":"4"}},{"id":2406540,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-09T21:24:52.000Z","date":"2022-02-04","kind":"purchase","acquired":true,"shares":2000,"price":2.45,"value":4900.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"The original Form 4, filed on February 8, 2022, is being amended by this Form 4 amendment to include shares purchased directly that were inadvertently omitted in the original filing."}],"balance_after":416156,"source":{"system":"sec-edgar","filing":"0001209191-22-008025","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919122008025/doc4a.xml","form_type":"4/A","original_submission_date":"2022-02-08"}},{"id":2406539,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-09T21:24:52.000Z","date":"2022-02-07","kind":"purchase","acquired":true,"shares":42100,"price":2.6076,"value":109779.96,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted-average price at which shares were purchased within a range between $2.50 and $2.6817. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee."}],"balance_after":1523335,"source":{"system":"sec-edgar","filing":"0001209191-22-008025","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919122008025/doc4a.xml","form_type":"4/A","original_submission_date":"2022-02-08"}},{"id":2406538,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-09T21:24:52.000Z","date":"2022-02-04","kind":"purchase","acquired":true,"shares":7900,"price":2.3109,"value":18256.11,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee."}],"balance_after":1481235,"source":{"system":"sec-edgar","filing":"0001209191-22-008025","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919122008025/doc4a.xml","form_type":"4/A","original_submission_date":"2022-02-08"}},{"id":2408572,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-08T23:52:44.000Z","date":"2022-02-07","kind":"purchase","acquired":true,"shares":42100,"price":2.6076,"value":109779.96,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted-average price at which shares were purchased within a range between $2.50 and $2.6817. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee."}],"balance_after":1523335,"source":{"system":"sec-edgar","filing":"0001209191-22-007837","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919122007837/doc4.xml","form_type":"4"}},{"id":2408571,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":83260,"kind":"person","name":"TIDMARSH GEORGE F","position":1,"cik":"0001287235","reported_name":"TIDMARSH GEORGE F","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-08T23:52:44.000Z","date":"2022-02-04","kind":"purchase","acquired":true,"shares":7900,"price":2.3109,"value":18256.11,"ownership":{"direct":false,"nature":"Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee."}],"balance_after":1481235,"source":{"system":"sec-edgar","filing":"0001209191-22-007837","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000120919122007837/doc4.xml","form_type":"4"}},{"id":2437927,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":122715,"kind":"person","name":"Feis Lawrence","position":1,"cik":"0001535069","reported_name":"Feis Lawrence","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":122716,"kind":"organization","name":"Feis Equities LLC","position":2,"cik":"0001891626","reported_name":"Feis Equities LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T20:59:54.000Z","date":"2022-01-10","kind":"other","acquired":false,"shares":731950,"price":10.2,"value":7465890.0,"ownership":{"direct":false,"nature":"See Footnote 2."},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In connection with Petra Acquisition, Inc.'s business combination, all shares were redeemed for cash at $10.20 per share, which is equal to the pro rata share of the aggregate amount in the Company's trust account."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The Common Stock is directly owed by Feis Equities LLC. Lawrence Feis, as the Managing Member of Feis Equities LLC will also be deemed to beneficially own the shares."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001376474-22-000016","document":"lf_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000137647422000016/lf_4.xml","form_type":"4"}},{"id":2561365,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.001 par value per share","published_at":"2021-09-23T20:21:06.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":611541,"price":10.08,"value":6164333.28,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":381106,"source":{"system":"sec-edgar","filing":"0001076809-21-000221","document":"paic20210923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680921000221/paic20210923.xml","form_type":"4"}},{"id":2561364,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.001 par value per share","published_at":"2021-09-23T20:21:06.000Z","date":"2021-09-22","kind":"sale","acquired":false,"shares":5,"price":10.08,"value":50.4,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":992647,"source":{"system":"sec-edgar","filing":"0001076809-21-000221","document":"paic20210923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680921000221/paic20210923.xml","form_type":"4"}},{"id":2561363,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock, $0.001 par value per share","published_at":"2021-09-23T20:21:06.000Z","date":"2021-09-21","kind":"sale","acquired":false,"shares":43000,"price":10.08,"value":433440.0,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":992652,"source":{"system":"sec-edgar","filing":"0001076809-21-000221","document":"paic20210923.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680921000221/paic20210923.xml","form_type":"4"}},{"id":2927855,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":144270,"kind":"person","name":"Fitzpatrick Sean H","position":1,"cik":"0001822077","reported_name":"Fitzpatrick Sean H","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-31T16:40:13.000Z","date":"2020-12-30","kind":"other","acquired":false,"shares":192962,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 30, 2020, the Sponsor forfeited at no cost 192,962 shares of common stock of the Issuer in connection with the expiration of the underwriters over-allotment option in connection with the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 30, 2020, the Sponsor forfeited at no cost 192,962 shares of common stock of the Issuer in connection with the expiration of the underwriters over-allotment option in connection with the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is a member of Petra Investment Holdings, LLC (\"Sponsor\"). He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in Petra Investment Holdings, LLC."}],"balance_after":1769538,"source":{"system":"sec-edgar","filing":"0001213900-20-045622","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000121390020045622/ownership.xml","form_type":"4"}},{"id":2928012,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":144279,"kind":"person","name":"TYPALDOS ANDREAS","position":1,"cik":"0001098013","reported_name":"TYPALDOS ANDREAS","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-12-31T11:35:39.000Z","date":"2020-12-30","kind":"other","acquired":false,"shares":192962,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On December 30, 2020, the Sponsor forfeited at no cost 192,962 shares of common stock of the Issuer in connection with the expiration of the underwriters over-allotment option in connection with the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 30, 2020, the Sponsor forfeited at no cost 192,962 shares of common stock of the Issuer in connection with the expiration of the underwriters over-allotment option in connection with the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is a member of Petra Investment Holdings, LLC (\"Sponsor\"). He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in Petra Investment Holdings, LLC."}],"balance_after":1769538,"source":{"system":"sec-edgar","filing":"0001213900-20-045618","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1098013/000121390020045618/ownership.xml","form_type":"4"}},{"id":2984452,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Units","published_at":"2020-11-12T21:47:01.000Z","date":"2020-11-09","kind":"sale","acquired":false,"shares":5000,"price":10,"value":50000.0,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":1035652,"source":{"system":"sec-edgar","filing":"0001076809-20-000236","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000236/primary_doc.xml","form_type":"4"}},{"id":3002401,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":144279,"kind":"person","name":"TYPALDOS ANDREAS","position":1,"cik":"0001098013","reported_name":"TYPALDOS ANDREAS","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Redeemable Warrant","published_at":"2020-10-21T17:09:05.000Z","date":"2020-10-16","kind":"other","acquired":true,"shares":83446,"price":1,"value":83446.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Includes securities underlying private warrants of the Issuer. The purchase of these warrants was made on a private placement basis and was consummated pursuant to the Sponsor's Subscription Agreement for Private Warrants, dated October 7, 2020, simultaneously with the underwriters partial exercise of their over-allotment option on October 16, 2020 in connection with the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each whole warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each warrant will become exercisable on the later of 30 days after the completion of the Issuer's initial business combination or October 7, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each warrant will expire five years after the completion of the Issuer's initial business combination."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is a member of Petra Investment Holdings, LLC (\"Sponsor\"). He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in Petra Investment Holdings, LLC."}],"balance_after":3233446,"derivative":{"underlying":"Common Stock","underlying_shares":83446},"source":{"system":"sec-edgar","filing":"0001213900-20-032604","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1098013/000121390020032604/ownership.xml","form_type":"4"}},{"id":3003120,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":144270,"kind":"person","name":"Fitzpatrick Sean H","position":1,"cik":"0001822077","reported_name":"Fitzpatrick Sean H","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Redeemable Warrant","published_at":"2020-10-20T17:56:37.000Z","date":"2020-10-16","kind":"other","acquired":true,"shares":83446,"price":1,"value":83446.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F2","text":"Includes securities underlying private warrants of the Issuer. The purchase of these warrants was made on a private placement basis and was consummated pursuant to the Sponsor's Subscription Agreement for Private Warrants, dated October 7, 2020, simultaneously with the underwriters partial exercise of their over-allotment option on October 16, 2020 in connection with the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each whole warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising transactions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each warrant will become exercisable on the later of 30 days after the completion of the Issuer's initial business combination or October 7, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each warrant will expire five years after the completion of the Issuer's initial business combination."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reporting person is a member of Petra Investment Holdings, LLC (\"Sponsor\"). He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in Petra Investment Holdings, LLC."}],"balance_after":3233446,"derivative":{"underlying":"Common Stock","underlying_shares":83446},"source":{"system":"sec-edgar","filing":"0001213900-20-032284","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1810560/000121390020032284/ownership.xml","form_type":"4"}},{"id":3004409,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Units","published_at":"2020-10-19T20:52:42.000Z","date":"2020-10-12","kind":"sale","acquired":false,"shares":20,"price":10,"value":200.0,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":1040652,"source":{"system":"sec-edgar","filing":"0001076809-20-000191","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000191/primary_doc.xml","form_type":"4"}},{"id":3004408,"issuer":{"id":8359,"kind":"organization","name":"REVELATION BIOSCIENCES, INC."},"owners":[{"id":117751,"kind":"organization","name":"GLAZER CAPITAL, LLC","position":1,"cik":"0001076809","reported_name":"GLAZER CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135278,"kind":"person","name":"GLAZER PAUL J","position":2,"cik":"0001133985","reported_name":"GLAZER PAUL J","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Units","published_at":"2020-10-19T20:52:42.000Z","date":"2020-10-09","kind":"sale","acquired":false,"shares":9328,"price":10,"value":93280.0,"ownership":{"direct":false,"nature":"See Footnote 1."},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by certain funds and accounts to which Glazer Capital, LLC, a Delaware limited liability company, serves as investment manager. Mr. Paul J. Glazer serves as the Managing Member of Glazer Capital, LLC. Each of Glazer Capital, LLC and Mr. Paul J. Glazer disclaims beneficial ownership of the securities reported herein except to the extent of such Reporting Person's pecuniary interest therein."}],"balance_after":1040672,"source":{"system":"sec-edgar","filing":"0001076809-20-000191","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1076809/000107680920000191/primary_doc.xml","form_type":"4"}}]}